What is PolyPid?
PolyPid Ltd. (Nasdaq: PYPD) is a specialized biopharma enterprise dedicated to enhancing surgical outcomes through advanced, locally administered therapeutics. At the core of its operations is the proprietary Polymer-Lipid Encapsulation matriX (PLEX) technology, which enables the precise, controlled release of Active Pharmaceutical Ingredients (APIs) over extended durations. This platform is currently being utilized to address significant unmet medical needs, most notably with its lead candidate, D-PLEX100, which is undergoing Phase 3 clinical trials for the prevention of surgical site infections. Beyond its surgical applications, the company is exploring the potential of its OncoPLEX technology for the treatment of solid tumors, including glioblastoma, demonstrating a robust commitment to high-impact medical innovation.
How much funding has PolyPid raised?
PolyPid has raised a total of $139.9M across 8 funding rounds:
Series A
$2.2M
Series B
$10.9M
Series C
$8.3M
Series D
$22M
Private Equity
$5.3M
Series E
$50M
Debt
$14.5M
Stock/Share Issuance
$26.7M
Series A (2011): $2.2M, investors not publicly disclosed
Series B (2014): $10.9M, investors not publicly disclosed
Series C (2015): $8.3M supported by GUIBOR and Financiere Saint James
Series D (2016): $22M featuring Shavit Capital and Aurum Ventures Private
Private Equity (2016): $5.3M backed by Xenia Venture Capital
Series E (2019): $50M with participation from Undisclosed
Debt (2024): $14.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $26.7M, investors not publicly disclosed
Key Investors in PolyPid
Shavit Capital
Shavit Capital is an investment practice founded in 2008 that specializes in late-stage investments in Israeli and Israeli-related companies, focusing on firms with proven technologies and strong management teams.
Xenia Venture Capital
Xenia Venture Capital is a publicly traded hi-tech investment company on the Tel Aviv Stock Exchange, primarily focused on investing in high tech and med tech sectors in Israel.
Aurum Ventures Private
Aurum Ventures is a specialized real estate investment and asset management company headquartered in Mumbai, India, that also emphasizes technology-led innovation in the real estate ecosystem.
What's next for PolyPid?
With the successful closure of this major enterprise-level funding, PolyPid is well-positioned to execute its strategic roadmap. The primary focus remains the completion of Phase 3 trials for D-PLEX100, a critical step toward regulatory approval and commercialization. Furthermore, the company is expected to allocate resources toward the preclinical development of its oncology portfolio, specifically the OncoPLEX platform. As PolyPid transitions from a clinical-stage entity toward a commercial-ready organization, the recent capital injection will be instrumental in scaling manufacturing capabilities and strengthening its market presence. Investors and stakeholders will be closely monitoring the company's progress in navigating the regulatory landscape and achieving its long-term therapeutic milestones.
See full PolyPid company page
